#256 Hydroxychloroquine with or without azithromycin for COVID-19
Reading Tools for Practice Article can earn you MainPro+ Credits
Join NowAlready a CFPCLearn Member? Log in
- Hydroxychloroquine 400 mg daily for 5 days was given to one group and both groups received conventional treatments.
- Number with negative PCR nasopharyngeal swab:
Day 7 | Adverse effects (examples diarrhea and elevated aspartate aminotransferase) | |
Control | 14/15 (93%) | 3/15 |
Hydroxychloroquine | 13/15 (87%) | 4/15 |
-
- Median time to temperature normalization was 1 day in each group.
- All patients survived.
- Limitations: not blinded. Much of the text was in Chinese.
- Number with negative PCR nasopharyngeal swab:
Day 3 | Day 6 | |
Control | 1/16 (6%) | 2/16 (13%) |
Hydroxychloroquine | 5/14 (36%) | 8/14 (57%) |
Hydroxychloroquine + Azithromycin | 5/6 (83%) | 6/6 (100%) |
- There are no studies evaluating the use of hydroxychloroquine to prevent COVID-19 infection.
- At least 23 other clinical trials currently in progress.3
- Both azithromycin and hydroxychloroquine are associated with an increased risk of sudden cardiac death from QT prolongation.4
- Applying early data, when we really need treatments and hope, is challenging. However, interventions that have not been verified to provide clinical/symptomatic benefits for hospitalized patients with COVID-19 are unlikely to benefit patients in primary care.